| [
|
| {
|
| "event_date": "2026-07-18",
|
| "ticker": "BMY",
|
| "asset": "mezigdomide",
|
| "event_type": "READOUT",
|
| "event_window": "Jul 18, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05552976",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05552976"
|
| },
|
| {
|
| "event_date": "2026-07-25",
|
| "ticker": "BMY",
|
| "asset": "deucravacitinib",
|
| "event_type": "READOUT",
|
| "event_window": "Jul 25, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT04036435",
|
| "source_url": "https://clinicaltrials.gov/study/NCT04036435"
|
| },
|
| {
|
| "event_date": "2026-07-27",
|
| "ticker": "REGN",
|
| "asset": "fianlimab",
|
| "event_type": "READOUT",
|
| "event_window": "Jul 27, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05608291",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05608291"
|
| },
|
| {
|
| "event_date": "2026-07-31",
|
| "ticker": "HRMY",
|
| "asset": "pitolisant",
|
| "event_type": "READOUT",
|
| "event_window": "Jul 2026",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06366464",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06366464"
|
| },
|
| {
|
| "event_date": "2026-07-31",
|
| "ticker": "LXRX",
|
| "asset": "sotagliflozin",
|
| "event_type": "READOUT",
|
| "event_window": "Jul 2026",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06481891",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06481891"
|
| },
|
| {
|
| "event_date": "2026-07-31",
|
| "ticker": "JAZZ",
|
| "asset": "zanidatamab",
|
| "event_type": "READOUT",
|
| "event_window": "Jul 31, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05152147",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05152147"
|
| },
|
| {
|
| "event_date": "2026-08-01",
|
| "ticker": "MRK",
|
| "asset": "tulisokibart",
|
| "event_type": "READOUT",
|
| "event_window": "Aug 1, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06052059",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06052059"
|
| },
|
| {
|
| "event_date": "2026-08-24",
|
| "ticker": "AZN",
|
| "asset": "camizestrant",
|
| "event_type": "READOUT",
|
| "event_window": "Aug 24, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT04711252",
|
| "source_url": "https://clinicaltrials.gov/study/NCT04711252"
|
| },
|
| {
|
| "event_date": "2026-08-30",
|
| "ticker": "PFE",
|
| "asset": "elranatamab",
|
| "event_type": "READOUT",
|
| "event_window": "Aug 30, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06152575",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06152575"
|
| },
|
| {
|
| "event_date": "2026-08-31",
|
| "ticker": "PHVS",
|
| "asset": "deucrictibant",
|
| "event_type": "READOUT",
|
| "event_window": "Aug 2026",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06669754",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06669754"
|
| },
|
| {
|
| "event_date": "2026-08-31",
|
| "ticker": "SBFM",
|
| "asset": "lerotinib",
|
| "event_type": "READOUT",
|
| "event_window": "Aug 2026",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT04415853",
|
| "source_url": "https://clinicaltrials.gov/study/NCT04415853"
|
| },
|
| {
|
| "event_date": "2026-08-31",
|
| "ticker": "SLGL",
|
| "asset": "patidegib",
|
| "event_type": "READOUT",
|
| "event_window": "Aug 2026",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06050122",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06050122"
|
| },
|
| {
|
| "event_date": "2026-08-31",
|
| "ticker": "LLY",
|
| "asset": "retatrutide",
|
| "event_type": "READOUT",
|
| "event_window": "Aug 2026",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06260722",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06260722"
|
| },
|
| {
|
| "event_date": "2026-09-01",
|
| "ticker": "INCY",
|
| "asset": "tafasitamab",
|
| "event_type": "READOUT",
|
| "event_window": "Sep 1, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT04824092",
|
| "source_url": "https://clinicaltrials.gov/study/NCT04824092"
|
| },
|
| {
|
| "event_date": "2026-09-27",
|
| "ticker": "BIIB",
|
| "asset": "litifilimab",
|
| "event_type": "READOUT",
|
| "event_window": "Sep 27, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT04961567",
|
| "source_url": "https://clinicaltrials.gov/study/NCT04961567"
|
| },
|
| {
|
| "event_date": "2026-09-28",
|
| "ticker": "MLTX",
|
| "asset": "sonelokimab",
|
| "event_type": "READOUT",
|
| "event_window": "Sep 28, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06768671",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06768671"
|
| },
|
| {
|
| "event_date": "2026-09-30",
|
| "ticker": "AZN",
|
| "asset": "datopotamab deruxtecan",
|
| "event_type": "READOUT",
|
| "event_window": "Sep 30, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06417814",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06417814"
|
| },
|
| {
|
| "event_date": "2026-09-30",
|
| "ticker": "KURA",
|
| "asset": "daunorubicin",
|
| "event_type": "READOUT",
|
| "event_window": "Sep 30, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT03117751",
|
| "source_url": "https://clinicaltrials.gov/study/NCT03117751"
|
| },
|
| {
|
| "event_date": "2026-09-30",
|
| "ticker": "DAN",
|
| "asset": "erwinia asparaginase",
|
| "event_type": "READOUT",
|
| "event_window": "Sep 30, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT03117751",
|
| "source_url": "https://clinicaltrials.gov/study/NCT03117751"
|
| },
|
| {
|
| "event_date": "2026-09-30",
|
| "ticker": "BIIB",
|
| "asset": "litifilimab",
|
| "event_type": "READOUT",
|
| "event_window": "Sep 30, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT04895241",
|
| "source_url": "https://clinicaltrials.gov/study/NCT04895241"
|
| },
|
| {
|
| "event_date": "2026-09-30",
|
| "ticker": "DAN",
|
| "asset": "mercaptopurine",
|
| "event_type": "READOUT",
|
| "event_window": "Sep 30, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT03117751",
|
| "source_url": "https://clinicaltrials.gov/study/NCT03117751"
|
| },
|
| {
|
| "event_date": "2026-09-30",
|
| "ticker": "AZN",
|
| "asset": "monalizumab",
|
| "event_type": "READOUT",
|
| "event_window": "Sep 30, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05221840",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05221840"
|
| },
|
| {
|
| "event_date": "2026-09-30",
|
| "ticker": "DAN",
|
| "asset": "nelarabine",
|
| "event_type": "READOUT",
|
| "event_window": "Sep 30, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT03117751",
|
| "source_url": "https://clinicaltrials.gov/study/NCT03117751"
|
| },
|
| {
|
| "event_date": "2026-09-30",
|
| "ticker": "AZN",
|
| "asset": "oleclumab",
|
| "event_type": "READOUT",
|
| "event_window": "Sep 30, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05221840",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05221840"
|
| },
|
| {
|
| "event_date": "2026-09-30",
|
| "ticker": "DAN",
|
| "asset": "pegaspargase",
|
| "event_type": "READOUT",
|
| "event_window": "Sep 30, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT03117751",
|
| "source_url": "https://clinicaltrials.gov/study/NCT03117751"
|
| },
|
| {
|
| "event_date": "2026-10-19",
|
| "ticker": "BMY",
|
| "asset": "deucravacitinib",
|
| "event_type": "READOUT",
|
| "event_window": "Oct 19, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05617677",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05617677"
|
| },
|
| {
|
| "event_date": "2026-10-20",
|
| "ticker": "BIIB",
|
| "asset": "litifilimab",
|
| "event_type": "READOUT",
|
| "event_window": "Oct 20, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05531565",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05531565"
|
| },
|
| {
|
| "event_date": "2026-10-26",
|
| "ticker": "NVS",
|
| "asset": "inclisiran",
|
| "event_type": "READOUT",
|
| "event_window": "Oct 26, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05360446",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05360446"
|
| },
|
| {
|
| "event_date": "2026-10-28",
|
| "ticker": "MRK",
|
| "asset": "belzutifan",
|
| "event_type": "READOUT",
|
| "event_window": "Oct 28, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05239728",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05239728"
|
| },
|
| {
|
| "event_date": "2026-10-29",
|
| "ticker": "MRK",
|
| "asset": "belzutifan",
|
| "event_type": "READOUT",
|
| "event_window": "Oct 29, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT04736706",
|
| "source_url": "https://clinicaltrials.gov/study/NCT04736706"
|
| },
|
| {
|
| "event_date": "2026-10-31",
|
| "ticker": "NUVL",
|
| "asset": "alectinib",
|
| "event_type": "READOUT",
|
| "event_window": "Oct 31, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT03178552",
|
| "source_url": "https://clinicaltrials.gov/study/NCT03178552"
|
| },
|
| {
|
| "event_date": "2026-10-31",
|
| "ticker": "VTRS",
|
| "asset": "cenerimod",
|
| "event_type": "READOUT",
|
| "event_window": "Oct 31, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05648500",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05648500"
|
| },
|
| {
|
| "event_date": "2026-10-31",
|
| "ticker": "IMMP",
|
| "asset": "eftilagimod alpha",
|
| "event_type": "READOUT",
|
| "event_window": "Oct 31, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05747794",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05747794"
|
| },
|
| {
|
| "event_date": "2026-10-31",
|
| "ticker": "NVS",
|
| "asset": "inclisiran",
|
| "event_type": "READOUT",
|
| "event_window": "Oct 2026",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT03705234",
|
| "source_url": "https://clinicaltrials.gov/study/NCT03705234"
|
| },
|
| {
|
| "event_date": "2026-10-31",
|
| "ticker": "SBFM",
|
| "asset": "minoxidil",
|
| "event_type": "READOUT",
|
| "event_window": "Oct 2026",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05888922",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05888922"
|
| },
|
| {
|
| "event_date": "2026-10-31",
|
| "ticker": "LLY",
|
| "asset": "retatrutide",
|
| "event_type": "READOUT",
|
| "event_window": "Oct 2026",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06297603",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06297603"
|
| },
|
| {
|
| "event_date": "2026-10-31",
|
| "ticker": "OGN",
|
| "asset": "tapinarof",
|
| "event_type": "READOUT",
|
| "event_window": "Oct 2026",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05172726",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05172726"
|
| },
|
| {
|
| "event_date": "2026-11-13",
|
| "ticker": "COGT",
|
| "asset": "midazolam",
|
| "event_type": "READOUT",
|
| "event_window": "Nov 13, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05646862",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05646862"
|
| },
|
| {
|
| "event_date": "2026-11-30",
|
| "ticker": "CGON",
|
| "asset": "cretostimogene grenadenorepvec",
|
| "event_type": "READOUT",
|
| "event_window": "Nov 2026",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06111235",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06111235"
|
| },
|
| {
|
| "event_date": "2026-11-30",
|
| "ticker": "DAN",
|
| "asset": "erwinia asparaginase",
|
| "event_type": "READOUT",
|
| "event_window": "Nov 30, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT03020030",
|
| "source_url": "https://clinicaltrials.gov/study/NCT03020030"
|
| },
|
| {
|
| "event_date": "2026-11-30",
|
| "ticker": "NAMS",
|
| "asset": "obicetrapib",
|
| "event_type": "READOUT",
|
| "event_window": "Nov 2026",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05202509",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05202509"
|
| },
|
| {
|
| "event_date": "2026-11-30",
|
| "ticker": "LLY",
|
| "asset": "orforglipron",
|
| "event_type": "READOUT",
|
| "event_window": "Nov 2026",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06649045",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06649045"
|
| },
|
| {
|
| "event_date": "2026-11-30",
|
| "ticker": "DAN",
|
| "asset": "pegaspargase",
|
| "event_type": "READOUT",
|
| "event_window": "Nov 30, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT03020030",
|
| "source_url": "https://clinicaltrials.gov/study/NCT03020030"
|
| },
|
| {
|
| "event_date": "2026-11-30",
|
| "ticker": "LLY",
|
| "asset": "tirzepatide",
|
| "event_type": "READOUT",
|
| "event_window": "Nov 2026",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06914895",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06914895"
|
| },
|
| {
|
| "event_date": "2026-12-01",
|
| "ticker": "VNDA",
|
| "asset": "tradipitant",
|
| "event_type": "READOUT",
|
| "event_window": "Dec 1, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT07446439",
|
| "source_url": "https://clinicaltrials.gov/study/NCT07446439"
|
| },
|
| {
|
| "event_date": "2026-12-02",
|
| "ticker": "MRK",
|
| "asset": "enlicitide decanoate",
|
| "event_type": "READOUT",
|
| "event_window": "Dec 2, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT07216482",
|
| "source_url": "https://clinicaltrials.gov/study/NCT07216482"
|
| },
|
| {
|
| "event_date": "2026-12-02",
|
| "ticker": "PFE",
|
| "asset": "mevrometostat",
|
| "event_type": "READOUT",
|
| "event_window": "Dec 2, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06629779",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06629779"
|
| },
|
| {
|
| "event_date": "2026-12-02",
|
| "ticker": "PFE",
|
| "asset": "ritlecitinib higher",
|
| "event_type": "READOUT",
|
| "event_window": "Dec 2, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT07029711",
|
| "source_url": "https://clinicaltrials.gov/study/NCT07029711"
|
| },
|
| {
|
| "event_date": "2026-12-02",
|
| "ticker": "PFE",
|
| "asset": "ritlecitinib lower",
|
| "event_type": "READOUT",
|
| "event_window": "Dec 2, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT07029711",
|
| "source_url": "https://clinicaltrials.gov/study/NCT07029711"
|
| },
|
| {
|
| "event_date": "2026-12-02",
|
| "ticker": "MRK",
|
| "asset": "rosuvastatin calcium",
|
| "event_type": "READOUT",
|
| "event_window": "Dec 2, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT07216482",
|
| "source_url": "https://clinicaltrials.gov/study/NCT07216482"
|
| },
|
| {
|
| "event_date": "2026-12-21",
|
| "ticker": "PFE",
|
| "asset": "ritlecitinib",
|
| "event_type": "READOUT",
|
| "event_window": "Dec 21, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06873945",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06873945"
|
| },
|
| {
|
| "event_date": "2026-12-26",
|
| "ticker": "INCY",
|
| "asset": "povorcitinib",
|
| "event_type": "READOUT",
|
| "event_window": "Dec 26, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06212999",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06212999"
|
| },
|
| {
|
| "event_date": "2026-12-30",
|
| "ticker": "INTS",
|
| "asset": "pazopanib",
|
| "event_type": "READOUT",
|
| "event_window": "Dec 30, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT03592472",
|
| "source_url": "https://clinicaltrials.gov/study/NCT03592472"
|
| },
|
| {
|
| "event_date": "2026-12-30",
|
| "ticker": "PFE",
|
| "asset": "vepdegestrant",
|
| "event_type": "READOUT",
|
| "event_window": "Dec 30, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05909397",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05909397"
|
| },
|
| {
|
| "event_date": "2026-12-31",
|
| "ticker": "PFE",
|
| "asset": "axitinib",
|
| "event_type": "READOUT",
|
| "event_window": "Dec 31, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05059522",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05059522"
|
| },
|
| {
|
| "event_date": "2026-12-31",
|
| "ticker": "AZN",
|
| "asset": "darolutamide",
|
| "event_type": "READOUT",
|
| "event_window": "Dec 2026",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT03903835",
|
| "source_url": "https://clinicaltrials.gov/study/NCT03903835"
|
| },
|
| {
|
| "event_date": "2026-12-31",
|
| "ticker": "PFE",
|
| "asset": "disitamab vedotin",
|
| "event_type": "READOUT",
|
| "event_window": "Dec 31, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05302284",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05302284"
|
| },
|
| {
|
| "event_date": "2026-12-31",
|
| "ticker": "IONS",
|
| "asset": "donidalorsen",
|
| "event_type": "READOUT",
|
| "event_window": "Dec 2026",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05392114",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05392114"
|
| },
|
| {
|
| "event_date": "2026-12-31",
|
| "ticker": "MRK",
|
| "asset": "ibrutinib",
|
| "event_type": "READOUT",
|
| "event_window": "Dec 31, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT01804686",
|
| "source_url": "https://clinicaltrials.gov/study/NCT01804686"
|
| },
|
| {
|
| "event_date": "2026-12-31",
|
| "ticker": "SMMT",
|
| "asset": "ivonescimab",
|
| "event_type": "READOUT",
|
| "event_window": "Dec 2026",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06767527",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06767527"
|
| },
|
| {
|
| "event_date": "2026-12-31",
|
| "ticker": "PFE",
|
| "asset": "lorlatanib",
|
| "event_type": "READOUT",
|
| "event_window": "Dec 31, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05059522",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05059522"
|
| },
|
| {
|
| "event_date": "2026-12-31",
|
| "ticker": "ABBV",
|
| "asset": "lutikizumab",
|
| "event_type": "READOUT",
|
| "event_window": "Dec 2026",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06468228",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06468228"
|
| },
|
| {
|
| "event_date": "2026-12-31",
|
| "ticker": "SNY",
|
| "asset": "migalastat",
|
| "event_type": "READOUT",
|
| "event_window": "Dec 31, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT04020055",
|
| "source_url": "https://clinicaltrials.gov/study/NCT04020055"
|
| },
|
| {
|
| "event_date": "2026-12-31",
|
| "ticker": "GNLX",
|
| "asset": "olvimulogene nanivacirepvec",
|
| "event_type": "READOUT",
|
| "event_window": "Dec 2026",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05281471",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05281471"
|
| },
|
| {
|
| "event_date": "2026-12-31",
|
| "ticker": "UTHR",
|
| "asset": "ralinepag",
|
| "event_type": "READOUT",
|
| "event_window": "Dec 2026",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT03683186",
|
| "source_url": "https://clinicaltrials.gov/study/NCT03683186"
|
| },
|
| {
|
| "event_date": "2026-12-31",
|
| "ticker": "DMAC",
|
| "asset": "recombinant human tissue kallikrein",
|
| "event_type": "READOUT",
|
| "event_window": "Dec 2026",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05065216",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05065216"
|
| },
|
| {
|
| "event_date": "2026-12-31",
|
| "ticker": "LLY",
|
| "asset": "retatrutide",
|
| "event_type": "READOUT",
|
| "event_window": "Dec 2026",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06662383",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06662383"
|
| },
|
| {
|
| "event_date": "2026-12-31",
|
| "ticker": "GILD",
|
| "asset": "sacituzumab govitecan hziy",
|
| "event_type": "READOUT",
|
| "event_window": "Dec 2026",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT04639986",
|
| "source_url": "https://clinicaltrials.gov/study/NCT04639986"
|
| },
|
| {
|
| "event_date": "2026-12-31",
|
| "ticker": "PFE",
|
| "asset": "talazoparib",
|
| "event_type": "READOUT",
|
| "event_window": "Dec 31, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05059522",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05059522"
|
| },
|
| {
|
| "event_date": "2026-12-31",
|
| "ticker": "VOR",
|
| "asset": "telitacicept",
|
| "event_type": "READOUT",
|
| "event_window": "Dec 31, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT07249632",
|
| "source_url": "https://clinicaltrials.gov/study/NCT07249632"
|
| },
|
| {
|
| "event_date": "2026-12-31",
|
| "ticker": "PFE",
|
| "asset": "utomilumab",
|
| "event_type": "READOUT",
|
| "event_window": "Dec 31, 2026",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05059522",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05059522"
|
| },
|
| {
|
| "event_date": "2027-01-04",
|
| "ticker": "AZN",
|
| "asset": "laroprovstat",
|
| "event_type": "READOUT",
|
| "event_window": "Jan 4, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT07000136",
|
| "source_url": "https://clinicaltrials.gov/study/NCT07000136"
|
| },
|
| {
|
| "event_date": "2027-01-04",
|
| "ticker": "MRK",
|
| "asset": "rescue medications",
|
| "event_type": "READOUT",
|
| "event_window": "Jan 4, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06356311",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06356311"
|
| },
|
| {
|
| "event_date": "2027-01-04",
|
| "ticker": "MRK",
|
| "asset": "supportive care measures",
|
| "event_type": "READOUT",
|
| "event_window": "Jan 4, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06356311",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06356311"
|
| },
|
| {
|
| "event_date": "2027-01-10",
|
| "ticker": "BMY",
|
| "asset": "mezigdomide",
|
| "event_type": "READOUT",
|
| "event_window": "Jan 10, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05519085",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05519085"
|
| },
|
| {
|
| "event_date": "2027-01-11",
|
| "ticker": "AZN",
|
| "asset": "laroprovstat",
|
| "event_type": "READOUT",
|
| "event_window": "Jan 11, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT07000123",
|
| "source_url": "https://clinicaltrials.gov/study/NCT07000123"
|
| },
|
| {
|
| "event_date": "2027-01-13",
|
| "ticker": "SMMT",
|
| "asset": "ivonescimab",
|
| "event_type": "READOUT",
|
| "event_window": "Jan 13, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06951503",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06951503"
|
| },
|
| {
|
| "event_date": "2027-01-15",
|
| "ticker": "IDYA",
|
| "asset": "darovasertib",
|
| "event_type": "READOUT",
|
| "event_window": "Jan 15, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05987332",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05987332"
|
| },
|
| {
|
| "event_date": "2027-01-15",
|
| "ticker": "MLTX",
|
| "asset": "sonelokimab",
|
| "event_type": "READOUT",
|
| "event_window": "Jan 15, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06641089",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06641089"
|
| },
|
| {
|
| "event_date": "2027-01-21",
|
| "ticker": "AMGN",
|
| "asset": "maridebart cafraglutide",
|
| "event_type": "READOUT",
|
| "event_window": "Jan 21, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06858839",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06858839"
|
| },
|
| {
|
| "event_date": "2027-01-29",
|
| "ticker": "PFE",
|
| "asset": "disitamab vedotin",
|
| "event_type": "READOUT",
|
| "event_window": "Jan 29, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05911295",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05911295"
|
| },
|
| {
|
| "event_date": "2027-02-04",
|
| "ticker": "MLTX",
|
| "asset": "sonelokimab",
|
| "event_type": "READOUT",
|
| "event_window": "Feb 4, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06641076",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06641076"
|
| },
|
| {
|
| "event_date": "2027-02-11",
|
| "ticker": "NVS",
|
| "asset": "inclisiran",
|
| "event_type": "READOUT",
|
| "event_window": "Feb 11, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT07102628",
|
| "source_url": "https://clinicaltrials.gov/study/NCT07102628"
|
| },
|
| {
|
| "event_date": "2027-02-14",
|
| "ticker": "LLY",
|
| "asset": "tirzepatide",
|
| "event_type": "READOUT",
|
| "event_window": "Feb 14, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT07481747",
|
| "source_url": "https://clinicaltrials.gov/study/NCT07481747"
|
| },
|
| {
|
| "event_date": "2027-02-22",
|
| "ticker": "AZN",
|
| "asset": "laroprovstat",
|
| "event_type": "READOUT",
|
| "event_window": "Feb 22, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06834932",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06834932"
|
| },
|
| {
|
| "event_date": "2027-02-26",
|
| "ticker": "AZN",
|
| "asset": "anifrolumab",
|
| "event_type": "READOUT",
|
| "event_window": "Feb 26, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05138133",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05138133"
|
| },
|
| {
|
| "event_date": "2027-02-28",
|
| "ticker": "LLY",
|
| "asset": "orforglipron",
|
| "event_type": "READOUT",
|
| "event_window": "Feb 2027",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06672549",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06672549"
|
| },
|
| {
|
| "event_date": "2027-02-28",
|
| "ticker": "GMAB",
|
| "asset": "rina",
|
| "event_type": "READOUT",
|
| "event_window": "Feb 2027",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06619236",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06619236"
|
| },
|
| {
|
| "event_date": "2027-02-28",
|
| "ticker": "GILD",
|
| "asset": "sacituzumab govitecan hziy",
|
| "event_type": "READOUT",
|
| "event_window": "Feb 2027",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05382286",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05382286"
|
| },
|
| {
|
| "event_date": "2027-03-01",
|
| "ticker": "NVO",
|
| "asset": "cagrilintide",
|
| "event_type": "READOUT",
|
| "event_window": "Mar 1, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT07011667",
|
| "source_url": "https://clinicaltrials.gov/study/NCT07011667"
|
| },
|
| {
|
| "event_date": "2027-03-13",
|
| "ticker": "RYTM",
|
| "asset": "setmelanotide",
|
| "event_type": "READOUT",
|
| "event_window": "Mar 13, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06760546",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06760546"
|
| },
|
| {
|
| "event_date": "2027-03-18",
|
| "ticker": "MRK",
|
| "asset": "ibrutinib",
|
| "event_type": "READOUT",
|
| "event_window": "Mar 18, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT04212013",
|
| "source_url": "https://clinicaltrials.gov/study/NCT04212013"
|
| },
|
| {
|
| "event_date": "2027-03-22",
|
| "ticker": "REGN",
|
| "asset": "fianlimab",
|
| "event_type": "READOUT",
|
| "event_window": "Mar 22, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06246916",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06246916"
|
| },
|
| {
|
| "event_date": "2027-03-24",
|
| "ticker": "NVS",
|
| "asset": "ianalumab",
|
| "event_type": "READOUT",
|
| "event_window": "Mar 24, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05639114",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05639114"
|
| },
|
| {
|
| "event_date": "2027-03-31",
|
| "ticker": "ARGX",
|
| "asset": "efgartigimod",
|
| "event_type": "READOUT",
|
| "event_window": "Mar 2027",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT04833894",
|
| "source_url": "https://clinicaltrials.gov/study/NCT04833894"
|
| },
|
| {
|
| "event_date": "2027-03-31",
|
| "ticker": "IONS",
|
| "asset": "olezarsen",
|
| "event_type": "READOUT",
|
| "event_window": "Mar 2027",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05681351",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05681351"
|
| },
|
| {
|
| "event_date": "2027-03-31",
|
| "ticker": "AAPG",
|
| "asset": "olverembatinib",
|
| "event_type": "READOUT",
|
| "event_window": "Mar 31, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06640361",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06640361"
|
| },
|
| {
|
| "event_date": "2027-03-31",
|
| "ticker": "MDGL",
|
| "asset": "resmetirom",
|
| "event_type": "READOUT",
|
| "event_window": "Mar 2027",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT04951219",
|
| "source_url": "https://clinicaltrials.gov/study/NCT04951219"
|
| },
|
| {
|
| "event_date": "2027-03-31",
|
| "ticker": "AZN",
|
| "asset": "rezvilutamide",
|
| "event_type": "READOUT",
|
| "event_window": "Mar 2027",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT07241416",
|
| "source_url": "https://clinicaltrials.gov/study/NCT07241416"
|
| },
|
| {
|
| "event_date": "2027-03-31",
|
| "ticker": "PFE",
|
| "asset": "ritlecitinib",
|
| "event_type": "READOUT",
|
| "event_window": "Mar 31, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06163326",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06163326"
|
| },
|
| {
|
| "event_date": "2027-03-31",
|
| "ticker": "NVS",
|
| "asset": "tisagenlecleucel",
|
| "event_type": "READOUT",
|
| "event_window": "Mar 31, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT04094311",
|
| "source_url": "https://clinicaltrials.gov/study/NCT04094311"
|
| },
|
| {
|
| "event_date": "2027-03-31",
|
| "ticker": "ONC",
|
| "asset": "zanubrutinib",
|
| "event_type": "READOUT",
|
| "event_window": "Mar 2027",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT04002297",
|
| "source_url": "https://clinicaltrials.gov/study/NCT04002297"
|
| },
|
| {
|
| "event_date": "2027-04-12",
|
| "ticker": "NVS",
|
| "asset": "ianalumab",
|
| "event_type": "READOUT",
|
| "event_window": "Apr 12, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05624749",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05624749"
|
| },
|
| {
|
| "event_date": "2027-04-14",
|
| "ticker": "PFE",
|
| "asset": "tofacitinib",
|
| "event_type": "READOUT",
|
| "event_window": "Apr 14, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT04624230",
|
| "source_url": "https://clinicaltrials.gov/study/NCT04624230"
|
| },
|
| {
|
| "event_date": "2027-04-20",
|
| "ticker": "AZN",
|
| "asset": "camizestrant",
|
| "event_type": "READOUT",
|
| "event_window": "Apr 20, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05774951",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05774951"
|
| },
|
| {
|
| "event_date": "2027-04-25",
|
| "ticker": "LLY",
|
| "asset": "lebrikizumab",
|
| "event_type": "READOUT",
|
| "event_window": "Apr 25, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06526182",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06526182"
|
| },
|
| {
|
| "event_date": "2027-04-27",
|
| "ticker": "AMGN",
|
| "asset": "maridebart cafraglutide",
|
| "event_type": "READOUT",
|
| "event_window": "Apr 27, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06987695",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06987695"
|
| },
|
| {
|
| "event_date": "2027-04-30",
|
| "ticker": "MRK",
|
| "asset": "ifinatamab deruxtecan",
|
| "event_type": "READOUT",
|
| "event_window": "Apr 30, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06203210",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06203210"
|
| },
|
| {
|
| "event_date": "2027-04-30",
|
| "ticker": "NVS",
|
| "asset": "iptacopan",
|
| "event_type": "READOUT",
|
| "event_window": "Apr 30, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06517758",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06517758"
|
| },
|
| {
|
| "event_date": "2027-05-02",
|
| "ticker": "PFE",
|
| "asset": "abrocitinib",
|
| "event_type": "READOUT",
|
| "event_window": "May 2, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06807268",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06807268"
|
| },
|
| {
|
| "event_date": "2027-05-11",
|
| "ticker": "NVO",
|
| "asset": "cagrilintide",
|
| "event_type": "READOUT",
|
| "event_window": "May 11, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT07220642",
|
| "source_url": "https://clinicaltrials.gov/study/NCT07220642"
|
| },
|
| {
|
| "event_date": "2027-05-12",
|
| "ticker": "NVO",
|
| "asset": "cagrilintide",
|
| "event_type": "READOUT",
|
| "event_window": "May 12, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT07220759",
|
| "source_url": "https://clinicaltrials.gov/study/NCT07220759"
|
| },
|
| {
|
| "event_date": "2027-05-18",
|
| "ticker": "TAK",
|
| "asset": "zasocitinib",
|
| "event_type": "READOUT",
|
| "event_window": "May 18, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06671483",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06671483"
|
| },
|
| {
|
| "event_date": "2027-05-19",
|
| "ticker": "MRK",
|
| "asset": "nemtabrutinib",
|
| "event_type": "READOUT",
|
| "event_window": "May 19, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05624554",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05624554"
|
| },
|
| {
|
| "event_date": "2027-05-31",
|
| "ticker": "TEVA",
|
| "asset": "deuruxolitinib",
|
| "event_type": "READOUT",
|
| "event_window": "May 2027",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT03898479",
|
| "source_url": "https://clinicaltrials.gov/study/NCT03898479"
|
| },
|
| {
|
| "event_date": "2027-05-31",
|
| "ticker": "LLY",
|
| "asset": "orforglipron",
|
| "event_type": "READOUT",
|
| "event_window": "May 2027",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT07613307",
|
| "source_url": "https://clinicaltrials.gov/study/NCT07613307"
|
| },
|
| {
|
| "event_date": "2027-05-31",
|
| "ticker": "VOR",
|
| "asset": "telitacicept",
|
| "event_type": "READOUT",
|
| "event_window": "May 2027",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06456580",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06456580"
|
| },
|
| {
|
| "event_date": "2027-06-02",
|
| "ticker": "NVS",
|
| "asset": "pelabresib",
|
| "event_type": "READOUT",
|
| "event_window": "Jun 2, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06401356",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06401356"
|
| },
|
| {
|
| "event_date": "2027-06-07",
|
| "ticker": "MRK",
|
| "asset": "belzutifan",
|
| "event_type": "READOUT",
|
| "event_window": "Jun 7, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05899049",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05899049"
|
| },
|
| {
|
| "event_date": "2027-06-18",
|
| "ticker": "REGN",
|
| "asset": "mibavademab",
|
| "event_type": "READOUT",
|
| "event_window": "Jun 18, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT07220772",
|
| "source_url": "https://clinicaltrials.gov/study/NCT07220772"
|
| },
|
| {
|
| "event_date": "2027-06-30",
|
| "ticker": "PFE",
|
| "asset": "binimetinib",
|
| "event_type": "READOUT",
|
| "event_window": "Jun 2027",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05615818",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05615818"
|
| },
|
| {
|
| "event_date": "2027-06-30",
|
| "ticker": "AZN",
|
| "asset": "datopotamab deruxtecan",
|
| "event_type": "READOUT",
|
| "event_window": "Jun 30, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06564844",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06564844"
|
| },
|
| {
|
| "event_date": "2027-06-30",
|
| "ticker": "PHVS",
|
| "asset": "deucrictibant",
|
| "event_type": "READOUT",
|
| "event_window": "Jun 2027",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05396105",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05396105"
|
| },
|
| {
|
| "event_date": "2027-06-30",
|
| "ticker": "IMMP",
|
| "asset": "eftilagimod alfa",
|
| "event_type": "READOUT",
|
| "event_window": "Jun 2027",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06726265",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06726265"
|
| },
|
| {
|
| "event_date": "2027-06-30",
|
| "ticker": "PFE",
|
| "asset": "encorafenib",
|
| "event_type": "READOUT",
|
| "event_window": "Jun 2027",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05615818",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05615818"
|
| },
|
| {
|
| "event_date": "2027-06-30",
|
| "ticker": "GMAB",
|
| "asset": "epcoritamab",
|
| "event_type": "READOUT",
|
| "event_window": "Jun 2027",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05578976",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05578976"
|
| },
|
| {
|
| "event_date": "2027-06-30",
|
| "ticker": "IMNN",
|
| "asset": "niraparib",
|
| "event_type": "READOUT",
|
| "event_window": "Jun 2027",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT03651206",
|
| "source_url": "https://clinicaltrials.gov/study/NCT03651206"
|
| },
|
| {
|
| "event_date": "2027-06-30",
|
| "ticker": "AZN",
|
| "asset": "rilvegostomig",
|
| "event_type": "READOUT",
|
| "event_window": "Jun 30, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06564844",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06564844"
|
| },
|
| {
|
| "event_date": "2027-06-30",
|
| "ticker": "GILD",
|
| "asset": "sacituzumab govitecan hziy",
|
| "event_type": "READOUT",
|
| "event_window": "Jun 2027",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05633654",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05633654"
|
| },
|
| {
|
| "event_date": "2027-06-30",
|
| "ticker": "AMGN",
|
| "asset": "sotorasib",
|
| "event_type": "READOUT",
|
| "event_window": "Jun 30, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05920356",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05920356"
|
| },
|
| {
|
| "event_date": "2027-06-30",
|
| "ticker": "JAZZ",
|
| "asset": "zanidatamab",
|
| "event_type": "READOUT",
|
| "event_window": "Jun 2027",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05615818",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05615818"
|
| },
|
| {
|
| "event_date": "2027-07-02",
|
| "ticker": "NVO",
|
| "asset": "ziltivekimab",
|
| "event_type": "READOUT",
|
| "event_window": "Jul 2, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05636176",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05636176"
|
| },
|
| {
|
| "event_date": "2027-07-05",
|
| "ticker": "AMGN",
|
| "asset": "tarlatamab",
|
| "event_type": "READOUT",
|
| "event_window": "Jul 5, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06211036",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06211036"
|
| },
|
| {
|
| "event_date": "2027-07-28",
|
| "ticker": "AZN",
|
| "asset": "datopotamab deruxtecan",
|
| "event_type": "READOUT",
|
| "event_window": "Jul 28, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06103864",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06103864"
|
| },
|
| {
|
| "event_date": "2027-07-30",
|
| "ticker": "GMAB",
|
| "asset": "acasunlimab",
|
| "event_type": "READOUT",
|
| "event_window": "Jul 30, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06635824",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06635824"
|
| },
|
| {
|
| "event_date": "2027-07-30",
|
| "ticker": "AZN",
|
| "asset": "darolutamide",
|
| "event_type": "READOUT",
|
| "event_window": "Jul 30, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05794906",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05794906"
|
| },
|
| {
|
| "event_date": "2027-07-30",
|
| "ticker": "PFE",
|
| "asset": "ritlecitinib",
|
| "event_type": "READOUT",
|
| "event_window": "Jul 30, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06072183",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06072183"
|
| },
|
| {
|
| "event_date": "2027-07-31",
|
| "ticker": "AZN",
|
| "asset": "dapagliflozin",
|
| "event_type": "READOUT",
|
| "event_window": "Jul 2027",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05374291",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05374291"
|
| },
|
| {
|
| "event_date": "2027-07-31",
|
| "ticker": "LLY",
|
| "asset": "retatrutide",
|
| "event_type": "READOUT",
|
| "event_window": "Jul 2027",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT07232719",
|
| "source_url": "https://clinicaltrials.gov/study/NCT07232719"
|
| },
|
| {
|
| "event_date": "2027-08-04",
|
| "ticker": "PFE",
|
| "asset": "elranatamab",
|
| "event_type": "READOUT",
|
| "event_window": "Aug 4, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05317416",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05317416"
|
| },
|
| {
|
| "event_date": "2027-08-07",
|
| "ticker": "AZN",
|
| "asset": "tezepelumab",
|
| "event_type": "READOUT",
|
| "event_window": "Aug 7, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT07363642",
|
| "source_url": "https://clinicaltrials.gov/study/NCT07363642"
|
| },
|
| {
|
| "event_date": "2027-08-09",
|
| "ticker": "BMY",
|
| "asset": "golcadomide",
|
| "event_type": "READOUT",
|
| "event_window": "Aug 9, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06356129",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06356129"
|
| },
|
| {
|
| "event_date": "2027-08-20",
|
| "ticker": "ARWR",
|
| "asset": "zodasiran",
|
| "event_type": "READOUT",
|
| "event_window": "Aug 20, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT07037771",
|
| "source_url": "https://clinicaltrials.gov/study/NCT07037771"
|
| },
|
| {
|
| "event_date": "2027-08-27",
|
| "ticker": "AZN",
|
| "asset": "ravulizumab",
|
| "event_type": "READOUT",
|
| "event_window": "Aug 27, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT07596784",
|
| "source_url": "https://clinicaltrials.gov/study/NCT07596784"
|
| },
|
| {
|
| "event_date": "2027-08-31",
|
| "ticker": "AAPG",
|
| "asset": "lisaftoclax",
|
| "event_type": "READOUT",
|
| "event_window": "Aug 2027",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06319456",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06319456"
|
| },
|
| {
|
| "event_date": "2027-08-31",
|
| "ticker": "LLY",
|
| "asset": "orforglipron",
|
| "event_type": "READOUT",
|
| "event_window": "Aug 2027",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06972459",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06972459"
|
| },
|
| {
|
| "event_date": "2027-08-31",
|
| "ticker": "CRNX",
|
| "asset": "paltusotine",
|
| "event_type": "READOUT",
|
| "event_window": "Aug 2027",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT07087054",
|
| "source_url": "https://clinicaltrials.gov/study/NCT07087054"
|
| },
|
| {
|
| "event_date": "2027-08-31",
|
| "ticker": "ABBV",
|
| "asset": "telisotuzumab adizutecan",
|
| "event_type": "READOUT",
|
| "event_window": "Aug 2027",
|
| "date_precision": "month",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06614192",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06614192"
|
| },
|
| {
|
| "event_date": "2027-08-31",
|
| "ticker": "MRK",
|
| "asset": "tocilizumab",
|
| "event_type": "READOUT",
|
| "event_window": "Aug 31, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT06084936",
|
| "source_url": "https://clinicaltrials.gov/study/NCT06084936"
|
| },
|
| {
|
| "event_date": "2027-09-01",
|
| "ticker": "NVO",
|
| "asset": "cagrilintide",
|
| "event_type": "READOUT",
|
| "event_window": "Sep 1, 2027",
|
| "date_precision": "day",
|
| "confidence": "medium",
|
| "source": "clinicaltrials",
|
| "nct_id": "NCT05669755",
|
| "source_url": "https://clinicaltrials.gov/study/NCT05669755"
|
| }
|
| ] |
